Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) EBT Margin (2022 - 2025)

Historic EBT Margin for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to 123.81%.

  • Atara Biotherapeutics' EBT Margin fell 692500.0% to 123.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.41%, marking a year-over-year increase of 1482200.0%. This contributed to the annual value of 66.24% for FY2024, which is 31573700.0% up from last year.
  • Atara Biotherapeutics' EBT Margin amounted to 123.81% in Q3 2025, which was down 692500.0% from 13.6% recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year EBT Margin high stood at 38.73% for Q1 2025, and its period low was 33789.59% during Q4 2022.
  • In the last 4 years, Atara Biotherapeutics' EBT Margin had a median value of 123.81% in 2025 and averaged 3694.09%.
  • Within the past 5 years, the most significant YoY rise in Atara Biotherapeutics' EBT Margin was 323623100bps (2023), while the steepest drop was -74660000bps (2023).
  • Atara Biotherapeutics' EBT Margin (Quarter) stood at 33789.59% in 2022, then soared by 96bps to 1427.28% in 2023, then soared by 97bps to 38.81% in 2024, then tumbled by -219bps to 123.81% in 2025.
  • Its last three reported values are 123.81% in Q3 2025, 13.6% for Q2 2025, and 38.73% during Q1 2025.